Evidence map›Paper›PMID 40400987›Full record

ArticleJournal of thoracic disease2025

Zhenzhen Liu, Na Li, Jiaqiu Liu, Jielin Li, Jingfei Sun, Franz Zehentmayr, Igor Gomez-Randulfe, Yuan Liang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhenzhen Liu *Department of Thoracic Cancer 1, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China.
Na Li *Department of Medical Oncology, Ward 2, Xincheng Hospital, Tieling Central Hospital, Tieling, China.
Jiaqiu LiuSchool of Graduate, Dalian Medical University, Dalian, China.
Jielin LiDepartment of Thoracic Cancer 1, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China.
Jingfei SunGraduate School of China Medical University, Shenyang, China.
Franz ZehentmayrDepartment of Radiation Oncology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Igor Gomez-RandulfeDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Yuan LiangDepartment of Thoracic Cancer 1, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, China.ORCID https://orcid.org/0009-0005-9415-8427

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Case Description: In November 2021, a 71-year-old Chinese male was diagnosed with metastatic Conclusions: To our knowledge, this is the first patient with

Indexed as

Bevacizumabcase reportchemotherapyimmunotherapySMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-UT)

Identifiers

PMID40400987
PMCPMC12090140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.